ArticleJournal of pediatric surgery2026
Thread- reinforced encapsulation devices (THRED) for therapeutic stem cell delivery.
Article in Journal of pediatric surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Encapsulation enhances stromal cell survival for safe neonatal therapy: a pilot study.World journal of pediatric surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionMesenchymal stem cells (MSCs) have been studied as potential therapeutic agents for various diseases. However, their widespread application has been limited, in part, due to the concern for tumorigenic transformation and lack of longevity in host environments secondary to immune-mediated destruction. Therefore, we set out to study an MSC encapsulation and delivery method with potential application in the treatment of intestinal ischemic diseases.
methodHuman vertebra bone adherent mesenchymal stem cells (vBA-MSCs) were encapsulated in an alginate-derived Thread Reinforced Encapsulation Device (THRED). The encapsulated cells were then tested for viability, ability to retain cell surface markers, and ability to synthesize and release cytokines. Furthermore, a mouse ischemia-reperfusion model was used to test the therapeutic potential of encapsulated MSCs.
resultsvBA-MSCs were successfully packaged in the experimental cell encapsulation device. Encapsulated MSCs remained viable and functional while retaining their cell surface markers. Furthermore, encapsulated MSCs improved mouse intestinal injury scores following intestinal ischemia and reperfusion injury. DISCUSSION: The THRED is a viable option to deliver mesenchymal stem cells during therapy. Further studies are needed to elucidate the ideal number of cells and the length of time needed to deliver optimal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.